Dr. David Spigel joined Sarah Cannon Research Institute in 2003. As Chief Scientific Officer, he oversees all scientific aspects of Sarah Cannon's clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to Sarah Cannon patients. He serves as a primary contact for the pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research. Additionally, he is an associate with Tennessee Oncology, PLLC.
He received his bachelor’s degree from Tulane University in New Orleans, and his MD degree from the University of Tennessee in Memphis. He then completed an internal medicine and chief residency at Indiana University Medical Center, followed by a fellowship in hematology and oncology at the Dana-Farber Cancer Institute in Boston. Dr. Spigel is board certified in medical oncology.
Jennifer Aversano, BSN, RN, OCN, BMTCN, is a double-certified oncology nurse navigator with a specialty in lung cancer at Advocate Lutheran General Hospital in Park Ridge, Illinois. In this role, she identifies all newly diagnosed lung cancer patients and helps them with any barriers and with navigation through the continuum of care. Ms. Aversano is also the point of contact for the lung cancer screening program, providing education to patients and follow-up recommendations to ordering physicians guided by the multidisciplinary lung tumor board.
She is the current system chair of the Advocate Navigation/Survivorship forum in the Advocate Health Care system, the largest integrated healthcare system in Illinois, which recently merged with Wisconsin’s largest healthcare system, Aurora Health Care. Ms. Aversano presented a poster with her colleagues at the 2018 American Society of Clinical Oncology (ASCO) annual meeting on a “Community Based Lung Cancer Screening Program: An Evaluation of the Initial Lung Cancer Screening CT Scan.”
She received her bachelor’s degree from Elmhurst College in Elmhurst, Illinois, and is currently pursuing a master’s degree in Nursing at Lewis University in Romeoville, Illinois.
Dr. Feller-Kopman serves as the Director of Bronchoscopy and Interventional Pulmonology at Johns Hopkins. He is an expert in the minimally invasive diagnosis and staging of lung cancer. His areas of clinical expertise include all aspects of interventional pulmonology, including minimal invasive diagnostic procedures to evaluate suspicious lung nodules and enlarged lymph nodes in the chest as well as the evaluation and management of malignant and non-malignant central airway obstruction. In addition, he specializes in the evaluation and management of pleural diseases with minimally invasive procedures such as ultrasound guided thoracentesis, indwelling pleural catheters and thoracoscopy with pleurodesis. He is a fellow of the American College of Chest Physicians and the American Thoracic Society, as member of the Miller-Coulson academy of Clinical Excellence at Johns Hopkins.
Dr. Feller-Kopman’s research focuses on the minimally invasive treatment of patients with malignant pleural effusion. Dr. Feller-Kopman co-founded the Interventional Pulmonary Outcomes Group (IPOG) whose mission is to provide and support multicenter prospective trials in the Interventional Pulmonary space. He is also involved with several projects investigating minimally invasive ways to diagnose and treat lung cancer. His goal is to advance the science of Interventional Pulmonology in order to improve the quality of life of patients with malignant pleural effusions and central airway obstruction as well as to develop new strategies to diagnosis and treat lung cancer.
He completed his internship and residency at Beth Israel Hospital, Harvard University; a Fellowship in Pulmonary and Critical Care, Combined Harvard Program (Massachusetts General Hospital, Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center; and a Fellowship: Interventional Pulmonary, Beth Israel Deaconess Medical Center, Harvard University. He is board certified in Internal Medicine, Pulmonary Disease, Critical Care Medicine, and Interventional Pulmonary.
Dr. Percy Lee is a Section Chief of Thoracic Radiation Oncology, and a Professor for the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston, TX.
Dr. Lee attended the Johns Hopkins University and graduated with the highest honors majoring in Biomedical Engineering with a concentration in Chemical Engineering. He attended Harvard Medical School and the Harvard-MIT Health Science and Technology program (HST) where he received his MD, and graduated magna cum laude. At Harvard, he was also a Howard Hughes Medical Institute fellow. He interned at the Massachusetts General Hospital and received specialty training in Radiation Oncology from Stanford University School of Medicine.
Nicholas Robert, MD, is currently the Medical Director, Data, Evidence & Insights, McKesson Life Sciences. In this role Dr. Robert oversees health economic outcomes research.
After being the clinical director of medical oncology at New England Medical Center (Tufts University), Dr. Robert joined Virginia Cancer Specialists in Fairfax,Virginia, where he served as Medical Director of the Research Program of the practice. He has also held positions as Chief, Hematology/Oncology Section, and Chair, Cancer Committee, at Inova Fairfax Hospital, as well as Chair of the ECOG Breast Committee. In addition, he has served as a faculty member of ASCO University.
The author of over 100 publications, Dr. Robert is a reviewer for several medical publications and the recipient of numerous research grants. He is a member of the American Society of Clinical Oncology (ASCO), and a former member of the Cancer Research Committee and past chair of the ASCO Research Community Forum. He was a member of the Eastern Cooperative Oncology Group and National Surgical Adjuvant Breast and Bowel Project.
A graduate of the McGill Medical School, Dr. Robert completed an internship and residency in Internal Medicine at the Royal Victoria Hospital in Montreal. Following a residency in Anatomic Pathology at Massachusetts General Hospital where he was Chief Resident, he continued his training in Hematology in Boston at Brigham and Women’s Hospital and in Medical Oncology at Dana-Farber Cancer Institute. He was a Fellow at Harvard Medical School.
He is board certified in Internal Medicine, anatomic pathology, medical oncology, and hematology.
Dr. Salgia earned his undergraduate degree summa cum laude in mathematics, biology, and chemistry, and then his MD, and PhD, from Loyola University in Chicago, Illinois, where he also completed fellowships in neurochemistry and physiology. He continued his postgraduate training with an internship and residency in internal medicine at The Johns Hopkins Hospital in Baltimore, Maryland, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston, Massachusetts, during which time he also served as a clinical fellow at Harvard Medical School in Boston.
Dr. Salgia is frequently invited to present his work at national and international conferences and symposia and is the recipient of several honors and awards. He is serving as a chartered member of NIH/NCI’s Tumor Progression and Metastasis Study Section, and he was also elected as the Translational Science Representative on NCI's Thoracic Malignancy Steering Committee.
Board-certified in internal medicine and medical oncology, Dr. Salgia is the current chief editor for Cancer Commons, and the co-chief editor for the Journal of Carcinogenesis. He also serves on the editorial advisory boards of four additional journals. Dr. Salgia has authored 286 peer-reviewed articles, reviews and editorials, one book, and 34 book chapters.
Dr. Shiller is board certified in Anatomic, Clinical, and Molecular Genetic Pathology following completion of residency at Baylor University Medical Center in Dallas, Texas, and fellowship at The Mayo Clinic in Rochester, Minnesota. Upon completion of training, Dr. Shiller established practice with Pathologists Biomedical Laboratories in Dallas, Texas, which services the majority of the Dallas-Fort Worth metroplex Baylor Scott and White Hospitals. As a result of her experience, she has served on multiple committees considering testing implementation and utilization. Dr. Shiller serves on the Quality Committee for the Baylor Sammons Cancer Center, and as assistant medical director for Cancer Genetics, primarily focusing on germline cancer predisposition, as well as Co-Assistant Medical Director for the Division of Molecular Medicine and Pathology. Finally, within the Baylor Scott and White system, Dr. Shiller has also served on the Baylor Medical Board.
As the emerging field of molecular pathology is rapidly evolving, Dr. Shiller has provided many educational forums to empower providers and break down barriers to implementation. She has embraced the opportunity to educate individuals at a larger scale through participation in presentations, video recordings, webinars, and content development. Consequently, Dr. Shiller has also served on steering committees and advisory boards for multiple entities.
An active member of the Association for Molecular Pathology (AMP), Dr. Shiller has also worked to foster a consistent dialogue between molecular pathology and oncology, assisting with developing the ASCO-sponsored Molecular Tumor Board. Quality, accuracy, relevance, timeliness, teamwork, and conscientious stewardship of the patient specimen—all with a patient-centered care focus—are considerations that Dr. Shiller is inspired to bring to reality with the ongoing integration of molecular diagnostics in the field of oncology. She is excited to serve on the Association of Community Cancer Centers Board of Trustees to further impact patient care positively with this focus.
Dr. Mark Socinski is the Executive Medical Director of the AdventHealth Cancer Institute in Orlando, Florida. Dr. Socinski was most recently the Director of the Lung Cancer Section at the University of Pittsburgh Medical Center, Clinical Associate Director of the University of Pittsburgh Lung Cancer SPORE, Co-Director of UPMC Lung Cancer Center of Excellence, and Co-Leader of the Lung Cancer Program at the University of Pittsburgh Cancer Institute.
Dr. Socinski holds membership in numerous professional societies such as the American College of Physicians, American Society of Clinical Oncology, Cancer and Leukemia Group B (Alliance), International Association for the Study of Lung Cancer, American College of Chest Physicians. He is also co-Chair Emeritus of the Thoracic Malignancies Steering Committee for the National Cancer Institute.
Dr. Socinski is well published in peer-reviewed literature including journals such as the Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer, and Lancet Oncology Dr. Socinski’s primary research interests reside in all aspects of clinical trials related to the thoracic oncology patient population. He also has been instrumental in the development of many cooperative group and investigator-initiated clinical trials.
Dr. Socinski received his medical degree from the University of Vermont, College of Medicine. His postdoctoral training included an internship and residency in internal medicine at the Beth Israel Hospital, Harvard Medical School and a medical oncology fellowship at the Dana-Farber Cancer Institute, Harvard Medical School.
As Director of the Virginia Cancer Specialists Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer, and sarcomas. He serves as Co-Chair of the US Oncology Thoracic Oncology Committee, Chair of the US Oncology Research Executive Committee, and member of the US Oncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine and serves as Assistant Professor of Oncology.
Throughout his career, Dr. Spira has been recognized as a “Top Doctor” in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award.
He earned his medical degree from the New York University School of Medicine. He completed his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993-1995), and Harvard University Scholarship (1987-1990). Dr. Spira also received his PhD from the New York School of Arts and Sciences.
Dr. Stiles is an Associate Professor of Cardiothoracic Surgery at New York-Presbyterian Hospital, Weill Cornell Medicine.
Dr. Stiles is a busy clinician, with expertise in the surgical management of lung cancer and other thoracic malignancies. Dr. Stiles is also an active basic science researcher focused on lung cancer. He is the Chair of the Board of Directors of the Lung Cancer Research Foundation (LCRF); Dr. Stiles is a grant reviewer for LCRF, the Thoracic Surgery Foundation, and the CDMRP Lung Cancer Research Program.
He is a member of numerous professional organizations, including the National Lung Cancer Roundtable, and an active advocate for lung cancer research and for patients.
As Executive Director, Cancer, Sanford Health,
Ms. Van De Steeg is responsible for strategy, business development, and clinical and financial operations of medical specialties and hospital operations including Cancer (Medical Hematology/Oncology, Radiation Oncology, Gynecology Oncology), Palliative Care, Genetic Counseling, Dermatology, Breast Health, Internal Medicine and Imaging.
Previously, she served as Executive Director, Health Inc., joint venture management organization for Mercy Medical Center – Sioux City and UnityPoint Health - St. Luke’s. In that capacity, she was responsible for financial performance; employee, employed-physician, and patient satisfaction for June E. Nylen Cancer Center, Sioux City, Iowa; Hospice of Siouxland; and Siouxland Paramedics, Inc.
Ms. Van De Steeg served on the Sioux Falls City Council member of YMCA in Sioux Falls, South Dakota (2002-2006), as Mayor Pro Tem (2004), and Mayor (2005). She is a board member for State of Iowa Cancer Consortium, and serves on the Policy Committee of the National Hospice and Palliative Care Organization.
She received an MA in Hospital and Health Administration from the University of Iowa, Iowa City, and is certified in healthcare compliance by the Health Care Compliance Association.
H. Jack West, MD, is Associate Clinical Professor and Executive Director of Employer Services at City of Hope Comprehensive Cancer Center in Duarte, California.
Prior to this, he was a medical oncologist and Medical Director of the Thoracic Oncology Program at Seattle Cancer Institute, in Seattle, Washington.
He founded and serves as President of the Global Resource for Advancing Cancer Education (GRACE), a nonprofit that provides free information for patients and caregivers dealing with cancer.
Dr. West serves as Web Editor of JAMA Oncology. He leads a wide range of continuing medical education programs and other educational programs, including hosting the podcast, West Wind.
Dr. West trained at Princeton University, University of Cambridge, Harvard Medical School, Brigham & Women’s Hospital, and Fred Hutchinson Cancer Research Center.
Ms. Ferris became involved with lung cancer advocacy following her mother’s death from the disease in 2008. After receiving a diagnosis of stage IV lung cancer in 2006, Andrea’s mother underwent numerous treatments and clinical trials at several major academic institutions to no avail. Together with her father, Andrea was her mother’s primary caregiver during this time. Determined to drive more money into lung cancer research, Andrea left the successful software company that she helped launch, to found Protect Your Lungs, an organization 100-percent focused on funding early detection research. In 2010, Andrea merged Protect Your Lungs with LUNGevity, a Chicago based organization, to form the nation’s leading lung cancer focused non-profit.
Andrea’s strong business background combined with her connections to the worlds of research and advocacy have enabled her to build the pre-eminent patient advocacy organization in the lung cancer space. LUNGevity funds translational research into both early detection and more effective treatments of lung cancer as well as a highly coveted Career Development Awards program. LUNGevity also fills unmet needs for people diagnosed with lung cancer by providing education, support, and survivorship programs. Recognizing the need to build awareness and understanding about lung cancer, LUNGevity has built the largest grassroots network of events and advocates across the country.
Nikki Martin brings more than 15 years of experience in healthcare advocacy to her current position as Director of Precision Medicine Initiatives at LUNGevity where she focuses on accelerating access to personalized healthcare for lung cancer patients. Prior to joining LUNGevity, Ms. Martin worked in Alliance & Advocacy Relations at Genentech where she championed awareness of unmet needs, driving change in the patient community. She led advocacy outreach related to Next Generation Sequencing and CMS' 14-day rule and expanding collaboration between CME providers and advocacy groups on provider and patient education on shared decision-making.
Previously, Ms. Martin held two roles at Grifols/Novartis Diagnostics, first as Associate Director, Global Communications and later as Associate Director, Global Public Affairs.
She earned her MA in International Trade Policy from the Middlebury Institute of International Studies, and a BS in Anthropology and a BA in Spanish from Santa Clara University.
This project is made possible by support from AstraZeneca.